How does it work?

Course format and duration

- Short courses are divided in several learning activities such as recorded lecture, reading, quiz, and forum that altogether run over 2 to 3 hours. The learning activities can be followed according to your wish. You can start a learning activity then stop and start another one, then come back later to the one you have firstly opened.
- \odot Once open, your training remains accessible until completion, and within one year.

Attendance and progress report


> The Central Office can quantify and analyse your own training attendance, workload and quiz progress per learning activity and per short course.

Evaluation and award

- When your training progress reaches 100%, you perform an online graded evaluation on your whole training content.
- O This evaluation consists in a quiz covering all your learning activities.
- O The training evaluation is successful if you reach at least a 80% good score.
- > You then receive an official Am2P certificate for your achieved competencies

How does it cost?

Affordable prices



Am2P supports worldwide pharmaceutical companies for their in-house training plans and provides quotes tailored to their needs in terms of content, duration and number of collaborators.

Ser more information, contact **Dr Karine Palin**: <u>am2p.office@am2p-courses.com</u>

Powered by





GAIN FAST AND SOLID EXPERTISE IN DRUG SAFETY WITH ONLINE SHORT COURSES



Am2P SHORT COURSES



North America Chapter

Basic Pharmacovigilance and Pharmacovigilance Regulations	\mathfrak{O}	0
Pharmacovigilance Regulations		
1. US/EU regulations: principles and comparison	3h	\$350
2. Overview of the Legal Basis of PV Regulations and the Role of the QPPV	3h	\$350
Labeling and Combination Products		
3. Principles of Labeling and Description of United States Prescribing Information (USPI)	3h	\$350
4. Pharmacovigilance in Combination Products and Regulations	3h	\$350
Adverse Drug Reporting		
5. From individual cases to the community impact of adverse drug reactions	2h	\$230
6. Aggregate reporting in the US	2,5h	\$290

Pharmacovigilance for Biologics	\simeq	\bigcirc
Vaccine Pharmacovigilance		
1. Vaccines Biologics Regulations	3h	\$350
Gene Therapy		
2. Gene therapy	3h	\$350
Pharmacovigilance for Human Cells, Tissues and Cellular a	nd Tissue-Based Pro	ducts

3. Pharmacovigilance for HCT/Ps	3h \$350
Targeted therapy	
4. Targeted Therapeutics	3h \$350

External databases/RWD/RWE	Ø	0
FDA System		
1. FDA Adverse Event Reporting System (FAERS)	2,5h	\$290
2. FDA Sentinel System	2,5h	\$290
Databases		
3. Health care records from large databases as a tool to study the use of medicines	2h	\$230
 Integrating Pharmacovigilance and consumption data analysis - uses, limitations and potentiality 	2h	\$230
Benefit Risk Assessment	\heartsuit	0
Benefit-risk assessment of medicines		
1. Principles and methods of benefit-risk assessment in decision-making of medicines	2h	\$230
2. Role of benefit-risk assessment and pharmaco-economics in decision-making of medicines	2,5h	\$290

APPLY ON-LINE START YOUR COURSE NOW!

4. Organization for risk management in the industry

5. Risk Evaluation and Mitigation Strategy (REMS)

Risk Management

3. Concepts in Risk Management

www.am2p-courses.com

3h \$350

3h \$350

2,2h \$260